ELVN
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Enliven Therapeutics, Inc. (ELVN) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Growth (D). The rating has held at C for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.5) | D (1.5) | C+ (2.7) | C+ (2.6) | C+ (2.6) | C (2.4) |
| 2026-11-04 | C+ (2.5) | D (1.4) | C+ (2.7) | C+ (2.8) | C+ (2.7) | C (2.4) |
| 2026-10-28 | C+ (2.5) | D (1.4) | C+ (2.7) | C+ (2.8) | C+ (2.7) | C (2.4) |
| 2026-10-21 | C+ (2.5) | D (1.4) | C+ (2.8) | C+ (2.7) | C+ (2.6) | C (2.4) |
| 2026-10-14 | C+ (2.5) | D (1.4) | C+ (2.8) | B- (2.9) | C+ (2.6) | C (2.4) |